The Long-Term Persistence Substudy (LTPS) of the Shingles Prevention Study (SPS) assessed persistence of zoster vaccine efficacy (VE) in a cohort of zoster vaccine recipients followed from 5 to 11 years post-vaccination. VE was lower in the LTPS than in SPS and the Short-Term Persistence Substudy, and was no longer statistically significant beyond 7 years post-vaccination. 
incidence of HZ. Analysis of vaccine efficacy for all three outcome measures in each year postvaccination showed declining efficacy from years seven through 11. The composite outcome of vaccine efficacy for the HZ burden of illness and the incidence of PHN was significantly greater than zero through year 10 post-vaccination, whereas vaccine efficacy for the incidence of HZ was significantly greater than zero only through year eight. The smaller study cohort in the LTPS and the use of historical controls introduces additional variability and potential bias into these results, but they were supported by sensitivity analyses.
Conclusions
Zoster vaccine efficacy for each study outcome decreased, but persisted, in the LTPS population.
Vaccine efficacy for the HZ burden of illness and the incidence of PHN appeared to persist into year ten following vaccination, whereas vaccine efficacy for the incidence of HZ appeared to persist only through year eight. years. Vaccine efficacy for all three study endpoints persisted through four years postvaccination (2, 3) . Details of the SPS design, the study endpoints, and the primary study results have been previously published (2, 3) . After completion of the SPS, follow-up for the persistence of zoster vaccine efficacy for a period ranging from 3.3 to 7.8 years post-vaccination was carried out in a cohort of 14,270 SPS participants from 12 of the 22 original study sites who were re-enrolled into a Short-Term Persistence Substudy (STPS) (4). In the STPS, zoster vaccine reduced the HZ burden of illness by 50.1% (95% CI 14.1, 71.0), the incidence of PHN by 60.1 (95% CI -9.8, 86.7%), and the incidence of HZ by 39.6% (95% CI, 18.2, 55.5) (4).
Combining the results of the SPS and STPS, there was evidence of persistence of vaccine efficacy through year five after vaccination, but persistence was uncertain after that point (4).
The Long-Term Persistence Substudy (LTPS) was undertaken to follow a cohort of vaccine recipients from the SPS for a period of five to ten years after vaccination to further assess the duration of zoster vaccine efficacy for the HZ pain and discomfort Burden of Illness (BOI), the incidence of PHN, and the incidence of HZ. analysis (6), and subjects were given famciclovir, if indicated. Local virus culture results were not recorded, but could be submitted with adjudication information. The Initial Zoster Impact Questionnaire (IZIQ) and Zoster Brief Pain Inventory (ZBPI) were used to record subjectreported pain and/or discomfort associated with HZ (2-4, 7, 8) . These responses were used to determine the HZ Severity of Illness Score and the presence or absence of clinically significant PHN (defined as a ZBPI worst pain score of >3 on a 0-10 scale persisting or appearing >90 days after HZ rash onset) (2-4, 7, 8) . The HZ severity-of-illness score (i.e., the burden of illness) for each case of HZ was defined as the area under the curve (AUC) of the ZBPI worst pain and/or discomfort severity plotted against time during the 182-day period after HZ rash onset (2, 3) . (CEC) (6) . In contrast to the SPS, in which every suspected case of HZ was evaluated by the CEC, CEC adjudication was only used to determine the diagnosis when the specimen for PCR diagnosis was missing or inadequate.
The HZ burden of illness was a composite measure reflecting the incidence of HZ and the severity and duration of HZ pain and/or discomfort in a population of subjects. It was defined as the sum of the HZ severity-of-illness scores of all of the evaluable cases of HZ in the group (e.g., the 60-69 year old zoster vaccine recipients). Subjects who did not develop HZ were assigned an HZ severity-of-illness score of zero (2).
Statistical methods. The definition of the HZ burden of illness, as well as methods for
calculating vaccine efficacy for study outcomes, have been previously published (2-4, 8, 9 ). The analysis of the incidence of HZ and PHN assumed a Poisson distribution for events and used a conditional exact method for calculating rates (10, 11, 12) . Data management and statistical programming were performed using SAS programming language (13) with exact confidence limits calculated using StatXact (14) . Vaccine efficacy for the HZ burden of illness and for the incidence of HZ and PHN were calculated for the entire LTPS period (primary analysis). Since there was no placebo control group, the incidence and burden of illness outcomes for the reference placebo population were estimated using historical control methodology and results from the placebo group in the SPS and STPS (16).
Three age-year adjusted models were employed to determine historical controls that varied with respect to the degree of inclusion of results from SPS and STPS and in incorporating a calendar-time effect (16) . Adjustment for age was included for the association of incidence of HZ with increasing age, and the experience of age-related effects on vaccine efficacy. In addition, in the analysis of the SPS and STPS, it was noted that the age-specific incidence of HZ in the placebo group increased over calendar time (i.e., a "calendar effect"), but there was no comparable increase in the incidence of PHN or in the HZ Severity-of-Illness Scores. Therefore, the calendar effect was included in the two models used in the determination of historical controls. The three approaches defined in the LTPS statistical analysis plan were: 1) conservative (sensitivity analysis #1): include only data from SPS with no calendar-time effect; 2) intermediate (primary analysis): include data from SPS with a calendar-year effect; and 3) contemporary (sensitivity analysis #3) include data from SPS and recently completed STPS with a calendar-year effect.
Analyses were stratified by age at randomization in the SPS into two pre-specified age groups:
60-69 years of age, and 70 years of age or older. Supportive analyses to assess the change in vaccine efficacy over each year of follow-up in the SPS, STPS, and LTPS were also completed for the three study outcomes. The incidence of HZ within a specific year post-vaccination was calculated by dividing the number of cases of HZ occurring within that year by the number of subject-years of follow-up for subjects in that year, then calculating vaccine efficacy as 1 - 
Objectives
The objectives of this study were to estimate the long-term vaccine efficacy of zoster vaccine in adults >60 years of age on the: 1) HZ pain burden of illness (BOI); 2) incidence of PHN, and 3)
incidence of HZ.
Results
Study population. From March 2006 to April 2007, 7625 subjects were screened and 6867 (90%) were enrolled into the LTPS (Table 1 ; Figure 1 ). The majority of subjects (6546) came from re-enrollment of STPS subjects, but 321 were vaccine recipients who had not enrolled in the STPS. The main reasons for subjects not enrolling (n=758) were: subjects declined participation (n=433, 57%); were considered unlikely to adhere to the protocol (n=37, 4.9%);
history of HZ (n=99, 13%). Of the 6867 subjects, 56.3% were male; age ranged from 64 to 95 (median, 74) years; 20.8% were >80 years of age; 97.8% were Caucasian. On average, subjects were six years older when they enrolled in the LTPS (mean, 74.5 years; SD= 5.8 years)
than when they were randomized in the SPS (mean, 68.3 years). Enrolled participants were, on average, younger than the subjects who were screened but did not enroll in the LTPS (mean age, 68.3 versus 69.6 years, respectively). Of this cohort, 88% (6043/6867) completed follow-up per study protocol. Reasons for discontinuation included death (5.8%), withdrawal from the study (5.6%), and lost to follow-up (0.6%).
Surveillance and follow-up of HZ cases. LTPS participants accrued 25,250 subject-years of follow-up during the 58 months of the study. Mean follow-up time (± standard deviation) was 3.74 ± 0.0.75 years. At study end, 6043 (88%) of the 6867 enrolled subjects completed closeout interviews, 399 (5.8%) died during the study, 382 (5.6%) withdrew, and 42 (0.6%) were lost to follow-up (Figure 1 ). Over the 58 months of surveillance in the LTPS, participants completed more than 90% of scheduled monthly contacts through the ATRS, and another 8.1% of monthly contacts were completed by telephone calls initiated by LTPS site personnel.
A total of 978 subjects with rashes and 13 subjects with unilateral pain/discomfort without rash were evaluated as suspected cases of HZ during the 58 months of the study. Of these, 347
(35.0%) were given a provisional diagnosis of HZ. Diagnostic specimens for central PCR assay
were collected from 326 (94%) of these suspected cases of HZ; PCR assay results were obtained for 317 (91%), and CEC adjudication was completed for 30 (9%). Of the suspected cases, 76%
(263 of 347) were determined to be evaluable cases of HZ, 259 (98%) by PCR and four (2%) by CEC adjudication. Two subjects each had two evaluable cases of HZ during the LTPS but, per protocol, only the first evaluable case was counted as a study endpoint in the primary and sensitivity analyses.
A HZ clinical case summary was obtained for each suspected case of HZ. The primary dermatome involved was: thoracic (48.7%), cervical (18.3%), trigeminal (14.8%; 12.1% V1), lumbar (10.5%), sacral (7.3%). . Among the 263 evaluable cases of HZ, 147 (56%) had prodromal pain, 224 (93%) had protocol-defined acute pain, and 108 (41%) had postherpetic pain, defined as a ZBPI worst pain score of three or greater more than 30 days after rash onset.
Complications of HZ were infrequent; those occurring in >1% of cases were allodynia (22%), scarring (3.4%), and ocular complications (including conjunctivitis, ptosis) (<2%). Only 4.2% of subjects were considered to be immunosuppressed at HZ diagnosis (i.e., were receiving corticosteroids or chemotherapy, had a diagnosis of malignancy, or were transplant recipients).
Safety.
No serious adverse events occurred during the LTPS that were judged possibly, probably, or definitely related to the vaccination. The cumulative mortality rate was approximately 1% per year, similar to that observed in the STPS and the SPS (2, 15).
Vaccine Efficacy. The HZ burden of illness was 1.74 per 1000 person-years in the study population; 1.58 per 1000 person-years among subjects ages 60 to 69 years at SPS entry and 1.98
per 1000 person-years among subjects >70 years of age at SPS entry ( Table 1 ). The incidence of protocol-defined PHN was 1.27 cases per 1000 person-years in the study population; 1.16 cases per 1000 person-years in subjects 60 to 69 years of age and 1.44 cases per 1000 person-years in subjects >70 years of age at SPS entry ( Table 2 ). The incidence of HZ in the study population was 10.3 cases per 1000 person-years; 10.1 cases per 1000 person-years in subjects 60 to 69 years of age and 10.7 cases per 1000 person-years in subjects >70 years of age at SPS entry (Table 1) For the primary analysis, the age-year adjusted historical control HZ burden of illness was 2.77 per 1000 person-years, the historical control incidence of PHN was 1.96 cases per 1000 person-years, and the historical control incidence of HZ was 13.1 cases per 1000 personyears, and these were used as constants in the denominator for vaccine efficacy calculations.
Vaccine efficacy for the three outcome measures for the LTPS population was 37.3% (95% CI:
26.7, 46.3) for the HZ burden of illness, 35.4% (95% CI: 8.8, 55.8) for the incidence of PHN, and 21.1% (95% CI: 10.9, 30.4) for the incidence of HZ (Figure 2 ). Vaccine efficacy for the HZ burden of illness and the incidence of PHN were similar, and showed a larger treatment effect than vaccine efficacy for the incidence of HZ.
Vaccine efficacy by year post-vaccination. The pooled analysis of the SPS and STPS published previously showed vaccine efficacy for both the HZ burden of illness and the incidence of HZ were significantly greater than zero for each year of follow-up through year five post-vaccination (4). The results for years 1 through 6 are presented again here (Table 3) -56.6, 38.1) in year 11 (Table 3 ). Vaccine efficacy for the incidence of PHN also declined from 26.3% (95% CI: -40, 66.3) in year 7 to 11.7% (95% CI: -100.0, 81.8) in year 11, with wider confidence intervals than for the other two study outcomes and only one year (year 9) in which the CI excluded zero (Table 3) . Although vaccine efficacy for all three study outcomes appears to decline with time post-vaccination, the wide confidence intervals for the by-year estimates of vaccine efficacy preclude year-to-year comparisons. Nevertheless, vaccine efficacy for the HZ burden of illness and the incidence of PHN appears to persist into year ten post-vaccination;
vaccine efficacy for the incidence of HZ appears to persist only through year eight following vaccination.
Discussion
In the LTPS, follow-up of a cohort of 6867 subjects who received zoster vaccine on enrollment into the SPS for a period ranging from 4.7 to 11.6 years post-vaccination, showed that zoster vaccine reduced the HZ burden of illness by 37.3%, the incidence of PHN by 35.4 %, and the incidence of HZ by 21.1%, compared to a historical control population. These estimates of zoster vaccine efficacy are 39% lower for the HZ burden of illness, 47% lower for the incidence of PHN, and 59% lower for the incidence of HZ than zoster vaccine efficacy in the SPS (61.1%, 66.5% and 51.3%, respectively), in which zoster vaccine and placebo recipients were followed from 0 to 4.9 years post-vaccination (2). The estimates of zoster vaccine efficacy from the LTPS are also 26% lower for the HZ burden of illness, 41% lower for the incidence of PHN, and 47%
lower for the incidence of HZ than those from the STPS (50.1%, 60.1% and 39.6%, respectively), in which SPS vaccine recipients were followed from 3. The comparable mortality rates observed among vaccine and placebo recipients in the SPS and STPS, and the absence of vaccine-related adverse events supports the long-term safety of zoster vaccine (2, 4, 15) .
Since the vast majority of the LTPS population was recruited from the STPS zoster vaccine recipients, it was not expected that the incidence of HZ would be lower in years seven and eight.
Over the LTPS follow-up period, the HZ incidence increased each year from 7.0 cases per 1000
person-years in year seven, to 11.4 cases per 1000 person-years in year ten and 13.6 cases per 1000 per person-years in year 11. However, we do not have the statistical power to detect a significant difference between years of follow-up, thus our discussion is based largely on the trends in point estimates from the primary and supportive analyses.
There are limitations in the LTPS that are important to note. First, the selection of the LTPS population was limited by resources, permitting the inclusion of only the 12 of the 22 original SPS sites that were included in the STPS. The study was designed to provide descriptive results with no pre-specified hypotheses for vaccine efficacy. The study population was limited in size to zoster vaccine recipients who could still be contacted at the 12 sites that participated in STPS.
Therefore, the study protocol was approved with sample size estimates with adequate power (>90 percent) to detect vaccine efficacy on the incidence of HZ greater than zero if the vaccine efficacy was as low as 20 percent, but the study was not powered to detect a specific time-point at which zoster vaccine efficacy fell below a pre-specified level. An age-adjusted historicalcontrol group was used as a proxy placebo (control) group, because SPS placebo recipients were offered zoster vaccine after completion of the SPS, and thus could not serve as a placebo control group for the LTPS. The data available for calculating historical controls was derived from placebo recipients followed in the SPS and STPS, and there was limited clinical data for modeling projected rates. Several alternative models were evaluated, and two were chosen for sensitivity analyses (16) . The smaller cohort in the LTPS and the necessary use of historical controls introduced additional variability and potential bias into the LTPS results. However, sensitivity analyses support the results of the primary analysis (Figures 2 and 3 ).
In conclusion, there was evidence of decreasing, but persisting, zoster vaccine efficacy for the HZ burden of illness, the incidence of PHN, and the incidence of HZ in the LTPS population, 
